Lyell Immunopharma amends LYL273 trial to Phase 1/2 design following safety gains
Lyell Immunopharma (NASDAQ:LYEL) announced on Monday that it has amended its ongoing U.S. Phase 1 clinical trial for LYL273 to a Phase 1/2 design.
Lyell Immunopharma (NASDAQ:LYEL) announced on Monday that it has amended its ongoing U.S. Phase 1 clinical trial for LYL273 to a Phase 1/2 design.
Shattuck Labs (NASDAQ:STTK) announced positive top-line results from its Phase 1 clinical trial of SL-325, a novel Death Receptor 3 (DR3) blocking antibody.
Honeywell International (NASDAQ:HON) announced on Monday that it is reaffirming its full-year 2026 financial guidance as the company nears the final stages of its portfolio transformation.
Gamehaus Holdings (NASDAQ:GMHS) reported its unaudited financial results for the third quarter of fiscal year 2026, ended March 31, 2026.
American Battery Technology Company (NASDAQ:ABAT) announced today that it has successfully won its appeal with the U.S. Department of Energy (DOE) regarding the reinstatement of a competitive grant award.
Duluth Holdings (NASDAQ:DLTH) reported financial results for the first quarter of fiscal 2026, ended May 3, 2026, highlighting significant progress in operational efficiency despite a challenging retail environment.
Advanced Micro Devices (NASDAQ:AMD) announced plans to invest up to £2 billion in the United Kingdom over the next five years, a strategic move designed to accelerate AI innovation, scientific research, and technical workforce development.
Alvotech (NASDAQ:ALVO) announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for intravenous administration.
LENZ Therapeutics (NASDAQ:LENZ) and Everest Medicines announced an agreement on June 8, 2026, transferring the rights to develop, manufacture, and commercialize LNZ100—marketed in the United States as VIZZ—within Greater China.
The return of the USD/JPY exchange rate above the 160 level has revived concerns that Japan could once again become a catalyst for turbulence across global financial markets, including cryptocurrencies.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy